Log in to save to my catalogue

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitorin...

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitorin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2890361675

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundExtended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment intervals.MethodsThe NEXT-MS trial is an investigator-initiated prospective phase IV non-randomised study. Adults with a diagnosis...

Alternative Titles

Full title

Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2890361675

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2890361675

Other Identifiers

ISSN

0022-3050

E-ISSN

1468-330X

DOI

10.1136/jnnp-2023-332119

How to access this item